Ocrevus (J2350) cost and reimbursement per infusion

$60.689 per 1 mg is Part B's ASP+6% rate for Q4 2026. At the 600 mg maintenance dose the drug alone runs $36,413.40, and the patient's 20% coinsurance on the full claim (drug plus 96413 and 96415 × 2) is $7,320.69 once the $283 Part B deductible is met, with no annual out-of-pocket maximum to cap it on Original Medicare. Full explanation: How Medicare Part B drug cost sharing works →

Medicare pays J2350 per 1 mg billing unit, not per vial or per dose. A 600 mg dose is 600 billing units, drawn whole from two 300 mg vials with nothing left to discard, so JZ belongs on the claim and JW never does outside the pediatric 150 mg dose.

What the two initial infusions cost, before maintenance

The initial dose is split into two 300 mg infusions two weeks apart, each drawn whole from one 300 mg vial. Each infusion is 300 billing units of J2350, or $18,206.70 at the Q4 2026 rate. With 96413 for the first hour plus one unit of 96415 for the rest of the 2.5-hour infusion, $161.66 together, that claim is allowed at $18,368.36, and the patient's 20% coinsurance is $3,673.67 ($3,641.34 on the drug, $26.65 on 96413, $5.68 on 96415) once the deductible is met.

The first year holds three infusions: the two 300 mg initial doses two weeks apart, then the first 600 mg maintenance dose six months after infusion 1. Across the three, the drug alone totals $72,826.80 — $18,206.70 twice, then $36,413.40. Each claim also carries its own administration line and its own position against the Part B deductible, so the three are not added into a single first-year figure here.

The maintenance year

From the second year on, treatment settles into two 600 mg doses six months apart. At $36,603.45 allowed on each claim — drug plus 96413 and 96415 × 2 — a maintenance year allows $73,206.90 before Medicare's 2% sequester.

For the reference patient — 600 mg, 600 units, drug plus 96413 and 96415 × 2 — Medicare allows $36,603.45, and the Part B coinsurance on that is $7,320.69. Plans A, B, C, D, F, G, M and N cover that coinsurance in full, so those patients owe nothing per infusion once the $283 deductible is met. Plans K and L do not. The infusion that lands before the deductible is met costs a Plan K patient $3,915.05; every infusion after it costs $3,660.35. Two maintenance doses a year, at $3,660.35 of Plan K share each once the deductible is met, leave the patient a few hundred dollars short of the plan's $8,000 annual out-of-pocket maximum, and the three-infusion first year comes closer still. See what each Medigap plan (A–N) owes on this claim →

Only the letters that leave this patient a balance are listed. The full A–N grid, the high-deductible variants, Plan N’s office-visit carve-out and the MACRA restriction on Plans C and F are at Medigap Plans A–N.

Commercial payers negotiate their own rate for J2350, not ASP+6%. Our corpus holds published rates from 37 of 37 payer files, and Aetna's all-states median is $60.99 per unit, putting the 600-unit maintenance dose at $36,594.00 before benefits — a shade above Medicare's $36,413.40. That rate moves by payer and state, and the patient's actual bill turns on the specifics of their plan. Full explanation: How commercial drug reimbursement works →

Ocrevus Zunovo's per-milligram rate is lower — $47.287 against $60.689, $13.40 cheaper per mg. Its labeled dose is larger, 920 mg against 600 mg, and that outweighs the lower rate: $43,504.04 allowed for the drug on a Zunovo claim against $36,413.40 for the IV maintenance dose, $7,090.64 more every time. Zunovo also bills a different administration family, 96401 or 96372, rather than 96413 and 96415. Ocrevus Zunovo's own cost page →

On a commercial plan, the Ocrevus Copay Card takes the patient's cost to $0: up to $20,000 a calendar year toward the drug, and administration covered separately — up to $1,500 in the first calendar year and $1,000 each year after. It excludes Medicare, Medicaid and other government program patients. Uninsured patients may qualify for free drug through Genentech Access Solutions, capped at 400% of the federal poverty level.

One foundation fund covering multiple sclerosis is open today, at $8,000 a year: PAN Foundation's Multiple sclerosis (MS) fund, and unlike the manufacturer card, it accepts Medicare patients alongside commercial (not Medicaid), capped at 500% of the federal poverty level. Two more list multiple sclerosis but are currently closed: HealthWell Foundation's Multiple Sclerosis - Medicare Access fund and Good Days' Multiple Sclerosis fund. A closed fund can reopen without notice. See every program for this patient, with current status →

Sources: CMS ASP pricing files (Q4 2026); Medicare physician fee schedule (96413, 96415, 99214, national non-facility); Medicare Part B deductible (2026); Medicare Rights Center 2026 Medigap plan benefits chart; 37 commercial payer published price files (Q2 2026); Ocrevus Copay Card (ocrevus.com/patient/cost.html) and Genentech Access Solutions (genentech-pro.com/our-products/ocrevus.html) terms, verified May 28, 2026.

Reviewed September 21, 2026 by Erin Rose, CareCost Estimate founder. Methodology →